Biotechnology AstraZeneca/Daiichi’s Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor – AstraZeneca (NASDAQ:AZN) Read more
Biotechnology Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data – Immuneering (NASDAQ:IMRX) Read more
Stockmarkets Ayala completes patient enrollment for pivotal desmoid tumor study By biedexmarkets.com Read more
Biotechnology Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics’ AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002 – Elicio Therapeutics (NASDAQ:ELTX) Read more